Form 4 Filing for BridgeBio Oncology Therapeutics, Inc.

Raymond J. Kelleher, a director at BridgeBio Oncology Therapeutics, Inc., acquired 31,675 stock options on June 16, 2026. These options, with an exercise price of $7.73, are for the company's Common Stock and expire on June 15, 2036. The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, provided Kelleher continues to provide services to the company through the vesting date. The filing indicates that these are directly held shares.